Marco Lobba
Co-Founder & Chief Executive Officer CatenaBio
Marco Lobba, Ph.D., is the Co‑Founder and CEO of Catena Bio, where he leads the development of next‑generation site‑specific enzymatic conjugation technologies for advanced ADC and bioconjugate therapeutics. He earned his Ph.D. in Chemistry from UC Berkeley as a joint researcher in the laboratories of Jennifer Doudna and Matt Francis, focusing on innovative bioconjugation strategies and CRISPR delivery. Before founding Catena Bio, Marco served in quality leadership roles at Anresco Laboratories, managing ISO 17025 compliance, FDA audit response, and R&D initiatives. His background spans surface chemistry, protein interactions, and translational bioconjugation, bringing deep technical and operational expertise to the field.
Seminars
- Mitigating systemic toxicity through highly stable, site‑specific enzymatic conjugation that maintains linker integrity and minimizes premature payload release
- Enhancing anti‑tumor activity with hydrophilic, next‑generation linker architectures designed to improve solubility, reduce aggregation, and support dual‑payload loading
- Streamlining bioconjugation workflows with modular, enzyme‑driven manufacturing that enables reproducible DAR control, orthogonality, and scalability for complex ADC formats
